The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1245 Weight Loss articles
As GLP-1 medications like Ozempic, Wegovy, and Mounjaro gain prominence, the medical community and pharmaceutical giants are increasingly framing obesity as a chronic disease. This article delves into the multifaceted implications of this classification, examining its impact on treatment, policy, and patient perception, while questioning who truly benefits from this shift.
China's decision to include semaglutide on its National Essential Drug List marks a significant step in improving diabetes management across the nation, promising greater accessibility for millions.
A recent JAMA study reveals significant gaps in medical oversight for online GLP-1 prescriptions. Discover the risks and how to ensure safe access to weight loss medications.
Melanie Sivier chose the 'hard way' over bariatric surgery or new GLP-1 medications like Ozempic and Mounjaro, shedding nine dress sizes through dedication. Her story highlights the profound commitment required for sustainable change, and the often-overlooked physical aftermath.
New research from Yale University highlights critical gaps in the online prescribing of GLP-1 medications, raising serious concerns about patient safety and regulatory oversight.
The surge in GLP-1 medications for weight loss has led to a concerning trend: many online pharmacies are prescribing these powerful drugs with minimal to no doctor consultation, putting patients at significant risk.
Curious about peptides and their role in weight loss, cholesterol management, and overall health? This article breaks down what peptides are, how they work, and what the science says about popular options like GLP-1 agonists.
The rise of GLP-1 medications has revolutionized weight management. This comprehensive guide delves into semaglutide, tirzepatide, and other peptide therapies, offering insights into their efficacy, potential side effects, and how to track your progress effectively.
A new study compares GLP-1 and SGLT-2 inhibitors in patients with type 2 diabetes and atrial fibrillation, revealing significant differences in heart health outcomes.
